株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の喘息・慢性閉塞性肺疾患(COPD)治療薬市場

Global Markets for Asthma and COPD Drugs

発行 BCC Research 商品コード 100153
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
世界の喘息・慢性閉塞性肺疾患(COPD)治療薬市場 Global Markets for Asthma and COPD Drugs
出版日: 2012年08月17日 ページ情報: 英文 136 Pages
概要

世界の喘息・慢性閉塞性肺疾患(COPD)処方薬市場は、2011年に349億米ドルとなりました。同市場は、2012年には380億米ドルとなり、その後5年間はCAGR4.4%で拡大し、2017年には471億米ドルに達することが見込まれています。

当レポートでは、世界の喘息・慢性閉塞性肺疾患(COPD)治療薬市場を詳細に分析し、市場予測、現在認可され上市されている薬剤クラスの概要、企業プロファイルを交えた業界構造、規制環境についてまとめており、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 肺ドラッグデリバリー
  • 肺の状態と治療法
  • 呼吸器
    • 喘息
    • COPD
    • ドラッグデリバリー手法の利点と欠点
  • 薬剤開発プロセス
    • 疾患修飾薬の開発
    • 吸入薬の開発における技術的側面
    • 知的財産権
    • 薬剤開発
    • 複雑な規制承認プロセス
    • 規制上の課題
    • フロンガス使用の吸入器の撤廃
    • FDAの医薬品安全性警告
  • 業界参入企業
  • M&A
  • 競合要因
  • 主な動向
    • 世界の高齢者人口が喘息とCOPDの発症増加をもたらす
    • 新薬の登場が治療オプションの強化を後押し
    • 主要医薬品の特許切れとジェネリック医薬品の登場が市場を変える
  • 市場課題
  • アンメットニーズへの対応
  • 地域別分析
    • 南北アメリカ
    • EMRA
    • アジア

第4章 疾患の概要

  • 症状の比較
  • 喘息の概要
    • 子供の喘息
    • 成人の喘息
    • 世界における喘息の経済的負担
    • 喘息の分類
    • 原因とリスク要因
    • 診断
    • 喘息とCOPDの治療において認可された薬剤クラス
    • 薬物療法のアルゴリズム
  • COPD
    • COPDの分類
    • 原因とリスク要因
    • 診断
    • COPDの治療法
  • 地域別統計

第5章 薬剤クラス別市場

  • 気管支拡張薬
  • 生物学的製剤
  • 併用ICS/LABA薬剤

第6章 疾患別市場

  • 喘息治療薬
  • COPD治療薬

第7章 新興の動向と製品パイプラインのレビュー

  • 喘息遺伝子
  • 喘息の経口薬
  • 疾患修飾薬
  • 喘息の製剤
  • 新しい生物製剤 他

第8章 承認済み薬剤と特許のレビュー

第9章 企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM059B

Abstract

REPORT HIGHLIGHTS

The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.

Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.

The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.

COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications.

The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.

REASONS FOR DOING THE STUDY

Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a perceived high level of unmet need in this market in terms of treatment options for asthma and COPD patients.

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

SCOPE OF REPORT

The report provides a current market overview and projects future developments in the asthma and COPD drugs market over the period from 2011 through 2017. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed.

The report includes the following major sections:

  • Disease overview.
  • Industry structure and competitive analysis including tiers of competition; regulatory aspects; competitive factors; and market needs, challenges, and trends
  • Overall market revenue forecast and current market shares as well as revenue forecast by major drug classes, disease indication, and geographical regions.
  • In-depth analyses of current drug classes.
  • Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development.

The report will also analyze product sales and demographics in three regional markets: The Americas (U.S., Canada, Latin/South America); Europe, Middle East, Russia, Africa (EMRA); and Asia (Japan, Australia/New Zealand, other Asian nations, including India and China).

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, U.S. Securities and Exchange Commission (SEC) filings, the U.S. Patent and Trademark Office (USPTO), MEDCO Health, World Health Organization (WHO), trade organizations and their publications, online databases, and the medical and scientific literature.

The base year for analysis and forecast is 2011. Revenue forecasts are provided for the period 2012 to 2017. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient populations; unmet market needs; existing product patent expiration dates; the impact of the generic market; and new market entrants and their value proposition and differentiation.

Values are given in U.S. dollars, forecasts are made in constant U.S. dollars, and growth rates are compounded. Currency conversions were made in June 2012. Growth rates were calculated based on existing and proposed device and equipment sales, at manufacturer pricing, during the forecast period.

INTENDED AUDIENCE

This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes.

INFORMATION SOURCES

The analysis and data presented in this report are based on information collected from a variety of industry sources, including the pharmaceutical manufacturers that currently market prescription drugs in this therapeutic area and research- based companies that develop new drug candidates for these indications, as well as end users of prescription drugs. Secondary information sources include company websites, financials, and other literature; SEC filings; patents issued by the USPTO; trade organizations and publications; online databases; and medical and scientific literature.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she has completed more than 20 reports for BCC.

Table of Contents

INTRODUCTION

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY3$150

  • Table Summary : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017
  • Figure Summary : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017

Chapter- 3: OVERVIEW

  • PULMONARY DRUG DELIVERY
  • PULMONARY CONDITIONS AND THERAPIES
  • RESPIRATORY SYSTEM
  • DRUG DEVELOPMENT PROCESS
  • INDUSTRY PLAYERS
  • ACQUISITIONS AND MERGERS
  • COMPETITIVE FACTORS
  • SIGNIFICANT TRENDS
  • MARKET CHALLENGES
  • FILLING UNMET NEEDS
  • REGIONAL ANALYSIS

Chapter- 4: DISEASE OVERVIEW

  • SYMPTOM COMPARISONS
  • ASTHMA OVERVIEW
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • REGIONAL STATISTICS

Chapter- 5: MARKETS BY DRUG CLASS

  • BRONCHODILATORS
  • BIOLOGICAL DRUGS
  • COMBINATION ICS/LABA DRUGS
  • Table 14 : PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS, THROUGH 2017

Chapter- 6: MARKETS BY DISEASE

  • ASTHMA DRUGS
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • Figure 11 : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2011

Chapter- 7: EMERGING TRENDS AND PRODUCT PIPELINE REVIEW

  • THE "ASTHMA GENE"
  • ORAL DRUGS FOR ASTHMA
  • DISEASE MODIFYING DRUGS
  • ASTHMA FORMULATIONS
  • COPD FORMULATIONS
  • NOVEL BIOLOGICS
  • ULTRA LONG-ACTING MUSCARINIC ANTAGONISTS
  • ULTRA LONG-ACTING B2 AGONISTS (ULTRA-LABA)
  • LAMA AND LABA COMBINATION DRUGS
  • ANTI-INFLAMMATORY DRUGS
  • ANTI-PROTEASE
  • CHEMOKINE ANTAGONISTS
  • PPAR AGONISTS
  • ASTHMA/COPD DRUG DEVELOPMENT, BY COMPANY
  • ASTHMA DEVICES

Chapter- 8: APPROVED DRUGS AND PATENT REVIEW

  • PATENT REVIEW
  • Table 43 : APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011
  • Table 44 : DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013

Chapter- 9: COMPANY PROFILES18$963

  • ACTIENT PHARMACEUTICALS
  • AEROVANCE, INC.
  • ALMIRALL, S.A.
  • AMGEN INC.
  • APTAR PHARMA
  • ARGENTA DISCOVERY, LTD.
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM GMBH
  • CHIESI FARMACEUTICI SPA
  • CORNERSTONE THERAPEUTICS
  • CYTOS BIOTECHNOLOGY AG
  • DEY PHARMA (MYLAN SPECIALTY L.P.)
  • FOREST LABORATORIES, INC.
  • GENENTECH, INC. (ROCHE)
  • GLAXO WELLCOME U.K., LTD.
  • MEDICINOVA
  • MEDICIS PHARMACEUTICAL
  • MEDIMMUNE
  • MERCK & CO., INC.
  • NOVARTIS PHARMA
  • NYCOMED INTERNATIONAL (TAKEDA INTERNATIONAL)
  • OSIRIS THERAPEUTICS, INC.
  • PFIZER, INC.
  • SEPRACOR, INC. (SUNOVION)
  • SKYEPHARMA PLC
  • TEVA PHARMACEUTICAL INDUSTRIES, LTD.
  • THERAVANCE
  • TOPIGEN PHARMACEUTICALS, INC. (PHARMAXIS LTD)
  • VECTURA GROUP PLC

List of Tables

  • Summary Table : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017
  • Table 1 : MARKETED ASTHMA AND COPD DRUG CLASSES
  • Table 2 : NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011
  • Table 3 : NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011
  • Table 4 : NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011
  • Table 5 : ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JANUARY 2008 TO JUNE 2012
  • Table 6 : MAJOR ASTHMA/COPD DRUGS THAT LOSE PATENT PROTECTION BETWEEN 2008 AND 2024
  • Table 7 : ASTHMA AND COPD SYMPTOM COMPARISONS
  • Table 8 : CLASSIFICATION OF ASTHMA, BY SYMPTOMS
  • Table 9 : ASTHMA AND COPD DRUG CLASSES
  • Table 10 : CLASSIFICATION OF COPD AND ASTHMA
  • Table 11 : PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE AMERICAS
  • Table 12 : PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE EMRA
  • Table 13 : PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN ASIA
  • Table 14 : PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS, THROUGH 2017
  • Table 15 : PROJECTED GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2017
  • Table 16 : SHORT-ACTING BETA-2 AGONISTS, WITH APPROVAL AND PATENT EXPIRY DATES, 2011
  • Table 17 : PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST BRONCHODILATORS, THROUGH 2017
  • Table 18 : LONG-ACTING BETA-2 AGONISTS, 2011
  • Table 19 : PROJECTED GLOBAL MARKET FOR LABA PRODUCTS, THROUGH 2017
  • Table 20 : ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA BY MANUFACTURER, 2011
  • Table 21 : PROJECTED GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2017
  • Table 22 : PROJECTED GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS BY TYPE, THROUGH 2017
  • Table 23 : INHALED CORTICOSTERIODS, 2011
  • Table 24 : PROJECTED GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2017
  • Table 25 : LEUKOTRIENE MODIFIERS, 2011
  • Table 26 : PROJECTED GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2017
  • Table 27 : PROJECTED GLOBAL MARKET FOR PDE-4 DRUGS, THROUGH 2017
  • Table 28 : PROJECTED GLOBAL MARKET FOR ASTHMA BIOLOGICAL DRUGS, THROUGH 2017
  • Table 29 : COMBINATION ICS/LABA DRUGS, 2011
  • Table 30 : PROJECTED GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH 2017
  • Table 31 : PROJECTED REVENUES FROM ASTHMA/COPD DRUGS BY REGION, THROUGH 2017
  • Table 32 : PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE AMERICAS REGION, THROUGH 2017
  • Table 33 : PROJECTED USE OF ASTHMA/COPD DRUGS IN THE AMERICAS' REGION, THROUGH 2017
  • Table 34 : PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE EMRA, THROUGH 2017
  • Table 35 : PROJECTED USE OF ASTHMA/COPD DRUGS IN THE EMRA REGION, THROUGH 2017
  • Table 36 : PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE ASIAN REGION, THROUGH 2017
  • Table 37 : PROJECTED USE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, THROUGH 2017
  • Table 38 : PROJECTED GLOBAL MARKET FOR ASTHMA PRESCRIPTION DRUGS, THROUGH 2017
  • Table 39 : PROJECTED GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2017
  • Table 40 : PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD DRUGS, THROUGH 2017
  • Table 41 : PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD PRESCRIPTION DRUGS, THROUGH 2017
  • Table 42 : ASTHMA/COPD PRODUCTS UNDER DEVELOPMENT, BY COMPANY, 2012
  • Table 43 : APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011
  • Table 44 : DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013
  • Table 45 : ASTHMA/COPD TREATMENT PATENTS, BY COMPANY, DISEASE, PATENT NUMBER, YEAR FILED, 2011 THROUGH 2012
  • Table 46 : ASTHMA/COPD TREATMENT PATENTS, BY NUMBER, COMPANY, DESCRIPTION, AND DATE ISSUED, 2011 THROUGH 2012
  • Table 47 : ASTHMA/COPD DRUG TREATMENT PATENTS ISSUED BETWEEN JANUARY 2011 AND MAY 2012, BY COMPANY

List of Figures

  • Summary Figure : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017
  • Figure 1 : GLOBAL BRONCHODILATOR MARKET, BY TYPE, 2012 AND 2017
  • Figure 2 : GLOBAL MARKET SHARE FOR BRONCHODILATORS BY COMPANY, 2011
  • Figure 3 : MARKET SHARE FOR LABA BRONCHODILATORS BY COMPANY, 2011
  • Figure 4 : MARKET SHARE OF ANTI-INFLAMMATORY DRUGS BY TYPE, 2012 AND 2017
  • Figure 5 : MARKET SHARE OF LEADING MANUFACTURERS OF INHALED CORTICOSTERIODS, 2011
  • Figure 6 : GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, BY MANUFACTURER, 2012 AND 2017
  • Figure 7 : MARKET SHARE OF MANUFACTURERS OF ICS/LABA, 2011
  • Figure 8 : MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE AMERICAS REGION, 2012 AND 2017
  • Figure 9 : MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE EMRA, 2012 AND 2017
  • Figure 10 : MARKET PERCENTAGE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, 2012 AND 2017
  • Figure 11 : GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2011
  • Figure 12 : MARKET SHARES OF LEADING MANUFACTURERS OF ASTHMA DRUGS, 2011
  • Figure 13 : MARKET SHARES OF LEADING MANUFACTURERS OF COPD DRUGS, 2011
  • Figure 14 : MARKET SHARES OF LEADING MANUFACTURERS OF COMBINATION ASTHMA/COPD DRUGS, 2011
  • Figure 15 : PERCENT OF REVIEWED PATENTS FOR ASTHMA, COPD, AND COMBINATION USE, JANUARY 2011 TO MAY 2012
  • Figure 16 : ASTHMA/COPD PATENTS, BY COUNTRY, 2011 THROUGH 2012
Back to Top